"Derui Intelligent Medicine" received US$52 million in Series B financing, and the AI-designed weight-loss drug has entered Phase 3 clinical trials

Text | Hu Xiangyun Editor | Hai Ruojing 36 Krypton learned that Derui Intelligent Medicine has recently completed a US$52 million Series B financing. Investors include leading RMB and US dollar funds, and Kaicheng Capital is the exclusive financial advisor. The funds raised will be used to upgrade and iterate the AI pharmaceutical engine Molecule Arts Platform (MAP), improve its multi-agent (Multi-Agent) collaboration system and clinical data-in-the-Loop (Clinical Data-in-the-Loop), promote the Phase III clinical and commercialization of the self-developed oral GLP-1 small molecule MDR-001, and expand other differentiated innovative drug pipelines. The vision of DeRui Intelligent Medicine is to become an AI Native biopharmaceutical company. The founder and CEO Niu Zhangming has many years of CTO experience in German AI medical listed companies. He believes that traditional new drug research and development relies heavily on the experience of senior experts, requiring the synthesis of hundreds or thousands of molecules through repeated trials and errors. But now, breakthroughs in AI technology are expected to continue to subvert this traditional path and transform the "trial and error" new drug research and development model like looking for a needle in a haystack into a data-driven, calculable and iterable "standardized creation." This is also the original intention of DeRui Intelligent Medicine to build MAP. Schematic diagram of the Molecule Arts Platform (MAP) technology platform of DeRui Intelligent Medicine (Source: DeRui Intelligent Medicine) According to reports, the Molecule Arts Platform (hereinafter referred to as "MAP") is divided into a three-layer architecture: the first layer is the AI design layer, which integrates the company's self-developed PharmkGPT biology platform, Molecule Pro small molecule pharmaceutical platform and Molecule Dance structural biology platform, which can cover the entire process from preclinical to IND submission for various types of drugs such as small molecules and peptides. The second layer of the wet and dry complementary experiment platform is mainly responsible for data supply. The dry experiment simulation system Proxima Matrix and the wet laboratory Proxima Foundary operate simultaneously to continuously produce high-quality training data to support AI model iterations. "De Rui Intelligent Medicine"